NEW YORK, 5 May 2026 — Brain Health, the new peer-reviewed journal launched today by Genomic Press, publishes in its inaugural issue a scientific tribute to J. Craig Venter, who died on 29 April 2026 in San Diego at the age of 79. The tribute, written by Dr. Julio Licinio, appears at https://doi.org/10.61373/bh026ob.0015.
Where most of the obituaries that have appeared in the days since Venter's death have framed him principally as a genomicist, the tribute in Brain Health foregrounds a part of his trajectory that maps directly onto the journal's own focus: his earliest major methodological breakthrough emerged inside neuroscience. As an intramural investigator at the National Institute of Neurological Disorders and Stroke, Venter pioneered the expressed sequence tag, a method for rapidly identifying brain-expressed genes that ran orders of magnitude faster than the prevailing techniques of the day. The acceleration was real. So was the institutional rupture that followed. NIH leadership pursued patents on thousands of partial gene sequences derived from the method, a position that James Watson, then leading the public human genome project, denounced as scientifically indefensible before resigning in protest. Venter himself opposed the patenting strategy. By 1992, he had departed.
Reading the arc backward from the synthetic cells of 2010 and 2016, that NINDS chapter can look like a prologue. Reading it forward, from inside neuroscience, it looks like the foundation. The expressed sequence tag was a brain-gene method first. The methodological intuition that followed, that whole-genome shotgun sequencing could outperform the painstaking hierarchical approaches preferred by senior figures in the field, grew from that earlier work.
"His years at the NIH National Institute of Neurological Disorders and Stroke produced both a methodological breakthrough and a political rupture," Licinio writes in the tribute. "The word impossible appeared often in his career, almost always coming from someone else, who was subsequently proved wrong."
The tribute traces what followed. After leaving NIH, Venter co-founded The Institute for Genomic Research with his then wife and scientific partner Claire M. Fraser. There, with Hamilton Smith, the team sequenced the genome of Haemophilus influenzae Rd, the first complete genome of any free-living organism, published in Science in 1995. The work relied on whole-genome shotgun sequencing, a strategy whose feasibility had been doubted by some of the most senior figures in genomics. Venter had submitted a grant application proposing exactly this approach. NIH had rejected it on the grounds that the method would not work. By the time the rejection arrived, the team had finished the sequencing and dispatched the manuscript.
Within five years of the Haemophilus paper, Venter had moved to Celera Genomics and produced the genome of Drosophila melanogaster, demonstrating that whole-genome shotgun sequencing could ascend to the scale of a complex multicellular eukaryote. That ascent positioned him to take on the human genome. The race between Celera and the publicly funded International Human Genome Sequencing Consortium, led by Francis Collins, ended in February 2001 with simultaneous publications in Science and Nature, separated by a single day. President Bill Clinton stood between Venter and Collins in the East Room of the White House on 26 June 2000 to announce the working drafts to the world, with Prime Minister Tony Blair joining by satellite from London.
Inspired by Darwin's voyage on HMS Beagle, Venter then turned to the oceans, sailing personally aboard his ninety-five-foot sloop Sorcerer II. The Sargasso Sea pilot study and the global circumnavigation results that followed opened the field of large-scale environmental metagenomics, yielding over six million new genes and the first systematic glimpses of marine microbial diversity at planetary scale. The expedition transformed Venter into one of the most visible scientific advocates for ocean health. He testified before the United States Senate on ocean pollution and argued, often from the deck of a boat he sailed himself, that the seas required the same urgent stewardship demanded of the atmosphere.
The most audacious chapter still lay ahead. In May 2010, Venter, Smith, Clyde Hutchison, Daniel Gibson, and colleagues reported the construction of Mycoplasma mycoides JCVI-syn1.0, the first cell whose genome had been chemically synthesized in the laboratory and bootstrapped to support living function. Six years later, the same team produced JCVI-syn3.0, the minimal synthetic cell, with only 473 genes, a stripped chassis approaching the lower bound of cellular life. These were the foundational experiments of synthetic biology as a working discipline, and they reframed long-standing questions about what a genome is and what it does.
"Genomics, synthetic biology, and ocean science each carry his fingerprints," Licinio writes. "Venter rearranged what biology could undertake, how quickly such undertakings could move, and who could presume to lead them. He carried himself with the directness of someone who had been told no by senior people early enough in his career to stop hearing the word as binding."
The Brain Health tribute closes on the through-line that gives the journal a particular vantage on his legacy. The methods Venter developed for identifying brain-expressed genes seeded the broader genomic infrastructure on which contemporary neuroscience now depends. The expressed sequence tag work, the rapid-sequencing methods that followed, and the synthetic biology platforms that emerged later all run through the toolkits used today by investigators studying neurodevelopmental disorders, neurodegeneration, psychiatric genomics, and brain-organoid biology. The continuity is rarely foregrounded in genomics retrospectives. From inside neuroscience, it is plain.
"The man who took us beyond what was considered possible is gone," Licinio writes in closing. "The questions he dared ask, and the methods he dared adopt, remain."
Venter received the National Medal of Science in 2008 and was elected to the American Philosophical Society. The J. Craig Venter Institute, which he founded and led for more than three decades, continues its work in San Diego and Rockville.
The tribute, "In memory of J. Craig Venter (1946–2026): The scientist who dared challenge the impossible and won," appears online on 5 May 2026 in Brain Health and is freely accessible at https://doi.org/10.61373/bh026ob.0015.
About Brain Health
Brain Health is a high-quality, peer-reviewed medical research journal published by Genomic Press, New York, dedicated to the science of lifelong brain resilience and longevity. The journal's scope spans molecular and cellular neuroscience, neuroimaging, electrophysiology, computational modeling, clinical trials, epidemiology, digital health, behavioral intervention science, psychology, normative data, and the social sciences and humanities. Editor-in-Chief: Ma-Li Wong. The inaugural issue is freely accessible at https://bh.genomicpress.com .
Visit the Genomic Press Virtual Library: https://issues.genomicpress.com/bookcase/gtvov/
Our media website is at: https://media.genomicpress.com/
Brain Health website: https://bh.genomicpress.com/
Genomic Press website: https://genomicpress.com/
